IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.
- Revenue from three verticals expected to rise 16.5% to $16.8 million
- EBITDA loss forecast narrows sharply to -$943K from -$6.3M in FY25
- Total revenue projected at $20.3 million, up 2.9% year-on-year
- Cost savings outperform targets, with disbursements down 33.7%
- IDT wins two Asia-Pacific RNA manufacturing awards
Guidance Upgrade Signals Operational Turnaround
IDT Australia Limited (ASX:IDT) has raised its financial guidance for FY26, projecting a 16.5% increase in revenue from its three core verticals to $16.8 million. More strikingly, the company expects its EBITDA loss to shrink dramatically to approximately $943,000, a sharp improvement from a $6.3 million loss in FY25. This marks an 85.1% reduction in EBITDA losses, signalling a significant operational turnaround.
The total revenue guidance also edges higher to $20.3 million, a 2.9% increase on the prior year, despite a marked reduction in disbursements by 33.7% to $3.6 million. This suggests a leaner cost structure and improved efficiency across IDT’s manufacturing and service operations.
Demand Momentum and Cost Discipline Drive Results
The upgrade reflects robust demand both locally and internationally for IDT’s drug manufacturing services. The company cites strong trading conditions and cost savings running ahead of expectations as the primary drivers behind the improved outlook. These cost efficiencies appear to be translating directly into a narrower EBITDA loss, underscoring the effectiveness of IDT’s ongoing strategic reset.
While the guidance figures remain unaudited and subject to final confirmation next month, the trajectory aligns with earlier forecasts that anticipated a significant earnings turnaround for FY26, supported by operational upgrades and strategic partnerships.
Industry Recognition Bolsters RNA Leadership Credentials
IDT’s progress in the RNA therapeutics space has not gone unnoticed. The company recently received two prestigious awards at the Asia-Pacific RNA Excellence Awards 2026 in Singapore: the Overall RNA Manufacturing Excellence Award and the Best Emerging RNA CDMO Award. These accolades highlight IDT’s growing stature in the competitive RNA contract development and manufacturing organisation (CDMO) market, reinforcing its position as a leader in this rapidly expanding sector.
The awards acknowledge the company’s innovation and commitment to advancing RNA research and manufacturing, which may help attract further business in this high-growth niche.
Looking Ahead to Audited Results and Market Positioning
IDT will release its full audited FY26 results next month, which will provide a clearer picture of the company’s financial health and operational progress. Investors will be watching to see if the final numbers confirm the upbeat guidance and how IDT plans to build on its momentum in RNA manufacturing and cost management.
Given the company’s recent strategic realignment and recognition in the RNA sector, the coming months could be pivotal in defining whether IDT can sustain this positive trajectory and convert industry accolades into tangible commercial gains.
Bottom Line?
IDT’s upgraded guidance and RNA awards suggest a company on the cusp of a turnaround, but the final audited results will be crucial to validate this momentum.
Questions in the middle?
- Will IDT’s audited FY26 results confirm the significant EBITDA improvement forecast?
- How sustainable are the cost savings driving the narrower losses?
- Can the RNA manufacturing awards translate into new contracts and revenue growth?